缬沙坦联合依那普利对充血性心力衰竭患者促炎细胞因子的影响

目的　观察缬沙坦与依那普利联合应用对充血性心力衰竭 (CHF)患者促炎细胞因子的影响。方法　入选CHF患者 82例 ,平均年龄 (5 2± 9)岁 ,随机分为治疗组 5 2例 ,对照组 30例。治疗组应用缬沙坦 4 0～ 80 m g/d加依那普利 10 mg/d,其余治疗同对照组 ,治疗观察共 8周。两组均于治疗前后分别测定血清肿瘤坏死因子 α(TNF- α)、白介素 6 (IL - 6 )和白介素 2 (IL - 2 )的水平。结果　两组治疗后促炎细胞因子的水平均降低 (P<0 .0 1) ,但治疗组与对照组比较降低更为明显 (P<0 .0 1)。结论　缬沙坦与依那普利联合应用可降低 CHF患者促炎细胞因子的血清水平 ,可能与其改善心功能和抑制促炎细胞因子生成有关 ,两药合用对控制 CHF的发生发展可能发挥更好的治疗作用。

Effect of valsartan and enalapril on the proinflammatory cytokine levels in patients with congestive heart failure

Objective To evaluate the effect of valsartan and enalapril on the proinflammatory cytokine levels in patients with congestive heart failure(CHF). Methods 82 patients receiving conventional therapy were randomly divided into the valsartan plus enalapril group(52 patients, valsartan 40~80mg/d and enalapril 10mg/d) and control group(30 patients), the proinflammatory cytokine levels were detected before and 8 weeks after therapy in two groups. Results The clinical symptoms of patients in valsartan plus enalapril group were improved markedly(P<0.05) and the levels of TNF-α,IL-6,IL-2 were significantly lower than those in control group(P<0.01). Conclusions Combining valsartan with enalapril decreased the levels of proinflammatory cytokine and improved cardiac function in patients with CHF.